February 25, 2026 – San Diego, California, USA
Bionano Genomics highlighted major scientific advancements in Optical Genome Mapping (OGM) during Day 2 of the Bionano Symposium 2026, presenting new research demonstrating the technology’s expanding role across oncology, cell therapy, and gene therapy development. The session, themed New Frontiers in Oncology and Bioprocessing Applications, featured 11 expert presentations from leading academic, clinical, and industry researchers showcasing how OGM is transforming detection of complex genomic structural variants and advancing precision medicine innovation.
OGM is emerging as a high-resolution genome analysis tool capable of detecting structural variants (SVs) — including insertions, deletions, translocations, and complex rearrangements — often missed by conventional cytogenetics, fluorescence in-situ hybridization (FISH), or sequencing. Presenters demonstrated that OGM delivers unbiased, genome-wide structural variant detection, offering unprecedented resolution in rare cancers and heterogeneous tumor types.
Expanding Precision Oncology Applications
Clinical research data presented at the symposium illustrated OGM’s growing role in cancer genomics. A prospective one-year study analyzing multiple myeloma samples showed strong concordance with FISH while uncovering additional structural complexity, including chromoanagenesis events and immunotherapy-relevant alterations. These findings reinforce OGM’s ability to expand genomic insight beyond traditional diagnostic approaches.
Further studies in rare sarcomas revealed that OGM detected clinically significant structural variants in over 70% of samples previously classified as normal by karyotyping. Researchers identified cryptic genomic rearrangements and novel gene fusions, demonstrating the technology’s value in uncovering hidden oncogenic drivers and enabling more accurate molecular stratification for experimental therapies.
Advertisement
In breast and ovarian cancer, investigators introduced an OGM-based assay capable of identifying homologous recombination deficiency (HRD) using genome-wide structural variant patterns. The assay achieved high predictive accuracy, highlighting the platform’s potential to enhance biomarker discovery and guide precision oncology treatment decisions.
Driving Innovation in Cell and Gene Therapy
Beyond oncology, the symposium underscored OGM’s critical applications in cell and gene therapy bioprocessing. Researchers demonstrated how genome-wide OGM surveillance can detect structural variants introduced during development of induced pluripotent stem cells (iPSCs) and engineered cell lines. These include off-target gene editing effects, culture-associated mutations, and reprogramming-related genomic alterations that may influence therapeutic safety and efficacy.
Speakers highlighted growing recognition of OGM by global regulatory and scientific bodies as a highly sensitive method for evaluating genome integrity in advanced therapies. The technology is increasingly being applied as a quality control framework to support manufacturing consistency, safety validation, and regulatory readiness in regenerative medicine programs.
Large-scale initiatives such as ultra-deep genomic mapping projects further demonstrated OGM’s ability to characterize highly complex cancer genomes at unprecedented resolution, providing a foundation for next-generation biomarker development and translational research.
Global Adoption and Research Momentum
Bionano Symposium 2026 drew more than 1,150 registered participants from 73 countries, reflecting accelerating global adoption of OGM technologies across research and clinical communities. Collaborative networks are also forming to standardize implementation, develop quality frameworks, and expand data sharing infrastructures supporting genomic medicine advancement.
Scientific leaders emphasized that OGM is reshaping genome analysis by revealing complex structural variation at a scale previously inaccessible, positioning the platform as a transformative enabler of oncology discovery, advanced therapy development, and genomic diagnostics innovation.
Source: Bionano Genomics press release
